AgeX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 · 2022 | |||
| REVENUES | |||
| Grant revenues | $77 | $ | - |
| Other revenues | 65 | 34 | |
| Total revenues | 142 | 34 | |
| Cost of sales | (40) | (13) | |
| Gross profit | 102 | 21 | |
| OPERATING EXPENSES | |||
| Research and development | 734 | 1,025 | |
| General and administrative | 9,328 | 5,971 | |
| Total operating expenses | 10,062 | 6,996 | |
| Gain on disposition of fixed assets | 73 | - | |
| Loss from operations | (9,887) | (6,975) | |
| OTHER EXPENSE, NET | |||
| Interest expense, net | (4,900) | (3,335) | |
| Change in fair value of warrants | (35) | (225) | |
| Other income, net | 11 | 13 | |
| Total other expense, net | (4,924) | (3,547) | |
| NET LOSS | (14,811) | (10,522) | |
| Net loss attributable to noncontrolling interest | 8 | 60 | |
| NET LOSS ATTRIBUTABLE TO AGEX | $(14,803) | $(10,462) | |
| NET LOSS PER COMMON SHARE: | |||
| BASIC AND DILUTED | $(13.72) | $(9.70) | |
| WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | |||
| BASIC AND DILUTED | 1,079 | 1,079 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.